Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Pliant Therapeutics Q3 2026 Results: Net Loss of $24.4M, Loss Narrows

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics, with its lead candidate PLN-101095 currently in Phase 1a/1b trials. The company reports significant net losses since inception and expects to require substantial additional capital to fund its ongoing research and development activities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-24.4-26.3
EPS (diluted, $ a share)$-0.39$-0.43

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PLRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Pliant Therapeutics, Inc.: key numbers

Share price
$0.6932Close, Nov 16
Market cap
$43M
Shares outstanding
61.99MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Pliant Therapeutics, Inc.

All →
4:12 PM ET 8-K
Financial Results

Pliant Therapeutics Financial Results

Pliant Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095. The company ended the quarter with $388.5 million in cash and equivalents, providing a projected cash runway into 2027. Key operational milestones included preclinical data for its integrin-mediated drug delivery platform and leadership appointments in medical and research roles.

Term
Q3 2026

“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform.”

Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.